KA/EN
Register
Medicines reference
Search
Search
Product

Metronidazole Irbit

Favourites

Metronidazole · Irbit Chemical Pharmaceutical Plant

1 form: tablet. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
250 mg, Tablet No label dose in the reference yet - Georgia Yes, human
In force until 16 Feb 2027
Human (Ministry of Health, RAMA)
In the register: მეტრონიდაზოლი ირბიტი 250 მგ, აბი
№ რ-034426
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Metronidazole Irbit 250 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Oral metronidazole for a proven or strongly suspected susceptible obligate-anaerobic infection or selected symptomatic giardiasis with environmental control; not routine empirical treatment of uncomplicated diarrhoea or chronic enteropathy
6.1/10
Situational / acceptable
vetman assessment

Metronidazole Irbit

250 mg, tablet, human medicine
Assessed clinical scopeDog · Oral metronidazole for a proven or strongly suspected susceptible obligate-anaerobic infection or selected symptomatic giardiasis with environmental control; not routine empirical treatment of uncomplicated diarrhoea or chronic enteropathy · By mouth
Care settingVeterinary-directed inpatient or outpatient course after diagnosis and antimicrobial review, with a measured patient-specific dose and reassessment rather than automatic repeat courses
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-034426 · Verified on 16 Oct 2026 Off-label use

A clinically credible but stewardship-limited drug for susceptible anaerobes or selected giardiasis, not routine diarrhoea care. This whole 250 mg human tablet is useful only when it matches the calculated canine dose; otherwise a veterinary or validated compounded form is preferable.

Regulatory and scientific credibility6.0/10

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Clinical efficacy7.0/10

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Safety and tolerability6.0/10

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

Clinical practicality5.0/10

The whole 250 mg tablet can match a limited medium-to-large-dog weight range, but it cannot accurately deliver many patient-specific doses; use a suitable veterinary strength or validated compound outside that range.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use metronidazole routinely for uncomplicated acute diarrhoea, haemorrhagic diarrhoea that responds to fluids, nonspecific dysbiosis or chronic enteropathy. Establish a defensible anaerobic/protozoal target and reassess the need for any antimicrobial.
  • Do not use after hypersensitivity to metronidazole, another nitroimidazole or an excipient. Stop and treat urgently for facial swelling, bronchospasm, collapse or anaphylaxis.
  • Stop metronidazole promptly for ataxia, nystagmus, tremor, seizure, altered mentation, weakness or peripheral neuropathy. Neurotoxicity can follow cumulative or prolonged exposure and has occurred in dogs at lower doses than historically assumed.
  • Severe hepatic dysfunction can reduce clearance and increase neurotoxicity. Adjust the regimen, avoid unnecessary duration and monitor clinical status; renal failure can permit metabolite accumulation.
  • Avoid unnecessary exposure during pregnancy or lactation and use only after an individual benefit-risk assessment. Human labels carry mutagenicity/carcinogenicity concerns, and feline in-vitro genotoxicity adds uncertainty rather than proving clinical cancer risk.
  • Review warfarin or other coumarins, phenobarbital, phenytoin, cimetidine, lithium, ciclosporin, busulfan and alcohol-containing preparations. Exposure or effect can change and targeted monitoring may be required.
  • Vomiting, nausea, anorexia, diarrhoea or hypersalivation can occur. Metronidazole can markedly disrupt the canine intestinal microbiome for weeks, so repeated empirical courses are not microbiota-sparing treatment.
  • This intensely bitter human tablet is recorded as a whole dosing unit. Do not call an unmeasured crushed-powder fraction an accurate veterinary dose; when the calculated dose does not match the unit, select a suitable veterinary strength or validated compounded liquid.
Assessment sources
  1. Metronidazole market audit2026
  2. Metronidazole tablet label2024
  3. VMD SPC 20252025
  4. EMA metronidazole assessment2023
  5. ENOVAT acute diarrhoea guideline2024
  6. Canine diarrhoea RCT2020
  7. Canine neurotoxicity series2018
  8. Canine microbiome study2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Oral metronidazole for a proven or strongly suspected susceptible obligate-anaerobic infection or selected symptomatic giardiasis with environmental control; not routine empirical treatment of uncomplicated diarrhoea or chronic enteropathy
5.2/10
Weak evidence support
vetman assessment

Metronidazole Irbit

250 mg, tablet, human medicine
Assessed clinical scopeCat · Oral metronidazole for a proven or strongly suspected susceptible obligate-anaerobic infection or selected symptomatic giardiasis with environmental control; not routine empirical treatment of uncomplicated diarrhoea or chronic enteropathy · By mouth
Care settingVeterinary-directed inpatient or outpatient course after diagnosis and antimicrobial review, with a measured patient-specific dose and reassessment rather than automatic repeat courses
vetman score 5.2/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-034426 · Verified on 16 Oct 2026 Off-label use

Metronidazole retains a narrow role for susceptible anaerobic infection or selected symptomatic giardiasis, but this whole 250 mg human tablet cannot accurately deliver a typical feline dose. The low score is mainly presentation-specific and reinforced by variable Giardia efficacy and safety uncertainty.

Regulatory and scientific credibility6.0/10

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Clinical efficacy6.5/10

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Safety and tolerability5.5/10

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

Clinical practicality1.0/10

This 250 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use metronidazole routinely for uncomplicated acute diarrhoea, haemorrhagic diarrhoea that responds to fluids, nonspecific dysbiosis or chronic enteropathy. Establish a defensible anaerobic/protozoal target and reassess the need for any antimicrobial.
  • Do not use after hypersensitivity to metronidazole, another nitroimidazole or an excipient. Stop and treat urgently for facial swelling, bronchospasm, collapse or anaphylaxis.
  • Stop metronidazole promptly for ataxia, nystagmus, tremor, seizure, altered mentation, weakness or peripheral neuropathy. Neurotoxicity can follow cumulative or prolonged exposure and has occurred in dogs at lower doses than historically assumed.
  • Severe hepatic dysfunction can reduce clearance and increase neurotoxicity. Adjust the regimen, avoid unnecessary duration and monitor clinical status; renal failure can permit metabolite accumulation.
  • Avoid unnecessary exposure during pregnancy or lactation and use only after an individual benefit-risk assessment. Human labels carry mutagenicity/carcinogenicity concerns, and feline in-vitro genotoxicity adds uncertainty rather than proving clinical cancer risk.
  • Review warfarin or other coumarins, phenobarbital, phenytoin, cimetidine, lithium, ciclosporin, busulfan and alcohol-containing preparations. Exposure or effect can change and targeted monitoring may be required.
  • Vomiting, nausea, anorexia, diarrhoea or hypersalivation can occur. Metronidazole can markedly disrupt the canine intestinal microbiome for weeks, so repeated empirical courses are not microbiota-sparing treatment.
  • This intensely bitter human tablet is recorded as a whole dosing unit. Do not call an unmeasured crushed-powder fraction an accurate veterinary dose; when the calculated dose does not match the unit, select a suitable veterinary strength or validated compounded liquid.
Assessment sources
  1. Metronidazole market audit2026
  2. Metronidazole tablet label2024
  3. VMD SPC 20252025
  4. EMA metronidazole assessment2023
  5. ENOVAT acute diarrhoea guideline2024
  6. CAPC Giardia guideline2026
  7. Feline giardiasis study2004
  8. Feline PK and genotoxicity2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Metronidazole250 mg
Formulation Type
Tablet
Administration route
By mouth
Registration
Georgia Yes, human
In force until 16 Feb 2027
Human (Ministry of Health, RAMA)
In the register: მეტრონიდაზოლი ირბიტი 250 მგ, აბი
№ რ-034426
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Metronidazole
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25 mg/kg Dog, Cat Bacterial Infection By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Metrobactin 250 mg tablets for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use in cases of hepatic disorders.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical
    In dogs, high doses can cause neurotoxicity: tremor, muscle spasms, ataxia and even seizures, especially after a long course. The risk rises when the recommended dose or treatment length is exceeded. If neurological signs appear, stop metronidazole and treat the signs.
    Sources: VMD SPC · VMD · MSD Vet Manual
  • Warning
    Studies in laboratory animals have shown inconsistent results with regard to teratogenic/embryotoxic effects of metronidazole. Therefore, use of this veterinary medicinal product during pregnancy is not recommended.
    Sources: VMD SPC · VMD
  • Warning
    Metronidazole is excreted in milk and use during lactation is therefore not recommended.
    Sources: VMD SPC · VMD
  • Warning
    tremors, muscle spasms, ataxia, and even convulsions
    Sources: MSD Vet Manual
  • Warning (Cat)
    Metronidazole in cats: neurotoxicity (ataxia, altered mentation, tremors, seizures) is reported with high doses and long courses (58 mg/kg a day for 6 months; 111-222 mg/kg a day; 73.5-147 mg/kg a day). Keep to the label dose and duration; stop the drug at the first neurological sign.

Known Drug Interactions

  • Major warning Metronidazole + Phenobarbital
    Phenobarbital may increase hepatic metabolism of metronidazole resulting in decreased serum concentration of metronidazole.
    Recommendation: Metronidazole may be less effective than expected in a patient receiving phenobarbital. Monitor clinical response.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same active ingredients 11

Same therapeutic group 48

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗